A detailed history of Creative Planning transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Creative Planning holds 53,569 shares of CRDF stock, worth $131,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,569
Previous 54,735 2.13%
Holding current value
$131,779
Previous $121,000 18.18%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$2.05 - $2.77 $2,390 - $3,229
-1,166 Reduced 2.13%
53,569 $143,000
Q2 2024

Aug 15, 2024

BUY
$2.22 - $5.89 $32,154 - $85,310
14,484 Added 35.98%
54,735 $121,000
Q1 2024

May 10, 2024

BUY
$1.46 - $5.91 $21,536 - $87,178
14,751 Added 57.85%
40,251 $214,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $31,920 - $51,539
-33,251 Reduced 56.6%
25,500 $37,000
Q3 2023

Nov 16, 2023

BUY
$1.38 - $2.18 $1,381 - $2,182
1,001 Added 1.73%
58,751 $81,000
Q2 2023

Jul 21, 2023

BUY
$1.37 - $1.95 $45,552 - $64,837
33,250 Added 135.71%
57,750 $84,000
Q4 2022

Feb 10, 2023

SELL
$1.22 - $1.66 $1,311 - $1,784
-1,075 Reduced 4.2%
24,500 $34,000
Q3 2022

Nov 03, 2022

BUY
$1.54 - $3.21 $39,385 - $82,095
25,575 New
25,575 $39,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $107M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.